(Q41622082)

5 October 2017

1 reference

title

Interferon beta treatment for multiple sclerosis: persisting questions (English)

1 reference

5 October 2017

D E Goodkin

1

1 reference

5 October 2017

publication date

1 July 1996

1 reference

Multiple Sclerosis Journal

5 October 2017

published in

1 reference

5 October 2017

volume

1

1 reference

5 October 2017

issue

6

1 reference

5 October 2017

page(s)

321-324

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100605

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100605

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100605

Side effect profile of interferon beta-1b in MS: results of an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100605

Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100605

An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600100605

10.1177/135245859600100605

21 January 2018

Identifiers

DOI

1 reference

5 October 2017

1 reference